T cell bispecific antibodies (TCBs) are an emerging class of immunotherapeutics with several TCBs approved by the FDA for the treatment of leukemias, lymphomas, and myelomas. TCBs label tumor cells with one of their ends, and attract immune cells with another end to coerce them into tumor cell killing. However, one major challenge in the development of TCBs are “on-target, off-tumor” toxicities at sites in the body that also express TCB-targeted antigens. A new collaboration of Jennifer Lewis’ group and researchers from the Roche Innovation Centers in Switzerland and Germany now created an immune-infiltrated human kidney organoid-on-chip model that allows kidney toxicity of TCBs.
Adding immunity to human kidney-on-a-chip adv eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Moving the needle on monitoring skin cancer sciencedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sciencedaily.com Daily Mail and Mail on Sunday newspapers.
Patients with melanoma, the most concerning form of skin cancer in which pigment-producing cells start to grow out of control, can benefit from existing immunotherapies, but by far not all of them do.
A Harvard scientist used Google Cloud Platform compute resources to construct an HPC clone to conduct heart disease study, according to a Reuters story, “a [.]